Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Reduced Liver Uptake of Arterially Infused Melphalan during Retrograde Rat Liver Perfusion with Unaffected Liver Tumor Uptake

Joost Rothbarth, Rolf W. Sparidans, Jos H. Beijnen, Leo J. Schultze Kool, Hein Putter, Cornelis J. H. van de Velde and Gerard J. Mulder
Journal of Pharmacology and Experimental Therapeutics November 2002, 303 (2) 736-740; DOI: https://doi.org/10.1124/jpet.102.037895

Abstract

Isolated hepatic perfusion (IHP) with melphalan is used for patients with nonresectable metastases confined to the liver. To improve the efficacy of IHP and to reduce the toxicity to the liver, reversion (retrograde perfusion) of the bloodstream through the liver in a rat model was studied. For liver tumor induction male WAG/Rij rats were inoculated with CC531 cells, a colorectal tumor cell line. After 11 to 12 days the tumor-bearing rat livers were perfused by single-pass perfusion through either the portal (orthograde) or caval vein (retrograde) for different time periods. During perfusion melphalan (160 μM) was infused in the hepatic artery. Melphalan concentrations were measured by high-performance liquid chromatography. A rapid extraction of melphalan by the liver occurred in the first 5 min, reaching steady state after 10 to 20 min for both perfusion directions. The melphalan concentration of the outflow perfusate was significantly higher in the retrograde perfusion compared with the orthograde perfusion. The melphalan content of the tumor tissue was unaffected by perfusion direction at any time point. To the contrary, the melphalan uptake in liver tissue was strongly influenced: the melphalan content after 40-min retrograde perfusion was 12% of that after orthograde perfusion. The average tumor/liver concentration ratio was 6 for orthograde perfusion and 30 for retrograde perfusion. In conclusion, retrograde IHP with continuous melphalan infusion in the hepatic artery provides a high tumor uptake of melphalan with potentially reduced liver toxicity compared with orthograde IHP.

Isolated hepatic perfusion (IHP) is a treatment for patients with nonresectable metastases confined to the liver, allowing local treatment with high-dose chemotherapy. Because of this high exposure, promising tumor responses and survival rates have been observed (Alexander et al., 1998; Vahrmeijer et al., 2000). However, the percentage of patients with complete remission is still very limited and toxicity remains a major complication. Therefore, new strategies for drug administration during IHP to improve the efficacy of IHP and to reduce the toxicity to the liver are still needed.

Anatomical studies show that metastasizing tumor cells entering the liver via the portal vein develop into liver tumors, which are mainly vascularized by the hepatic artery (Sigurdson et al., 1987). Studies of the blood supply of liver tumors show that the hepatic artery provides up to 95% of their total blood flow (Wang et al., 1994); contrary to normal liver tissue, the portal vein plays a minor role in the blood supply of liver tumors (Taylor et al., 1978).

The liver sinusoids are perfused with blood from both the portal vein and hepatic artery. Studies of the blood supply of the rat liver show that the hepatic arterioles terminate in the first one-third of the sinusoids (zone 1) via an indirect or direct pathway (Fig.1) (Rappaport, 1980; Watanabe et al., 1994). As a result, the arterial blood reaches all zones of the sinusoid in orthograde perfusion. However, during retrograde perfusion, i.e., using the portal vein for outflow instead of the caval vein, the arterial blood only reaches zone 1, the periportal parts (Pang et al., 1988). Thus, when IHP is performed in the retrograde way, whereas high-dose chemotherapy is only infused via the hepatic artery, the exposure of the whole liver to the cytostatic compound will be reduced, and so probably also liver toxicity. Therefore, retrograde perfusion potentially provides increased safety. As liver tumors obtain most of their blood supply from the hepatic artery, retrograde perfusion is not expected to affect the exposure of liver tumors to arterially administered cytostatic compounds.

Figure 1
Figure 1

Liver tumor model. Continuous melphalan infusion in the hepatic artery during either orthograde or retrograde single-pass liver perfusion.

To explore the consequences of altered flow direction on the treatment of liver tumors, we assessed the distribution and accumulation pattern of melphalan, the drug currently used by us in IHP (Vahrmeijer et al., 2000), infused in the hepatic artery during orthograde and retrograde single-pass liver perfusion in a rat liver model.

Materials and Methods

Chemicals.

Melphalan was purchased from GlaxoSmithKline (Zeist, The Netherlands). Just before administration a melphalan solution (16.4 mM) was prepared by dissolving 1 mg of melphalan in 200 μl of 0.09% (w/v) hydrochloric acid, which was subsequently diluted with ice-cold Gelofusine (Vifor Medical, Sempach, Switzerland), a colloid solution of 4% modified gelatin in 0.9% NaCl, to a concentration of 480 μM; pH was adjusted to 7.4 with 1 N NaOH. During the experiment the melphalan solution was kept on room temperature.

Tumor Model.

The CC531 tumor cell line used is a carcinoma of the colon, syngeneic for WAG/Rij rats (Marquet et al., 1984). The cells were cultured in medium that consisted of RPMI 1640 medium supplemented with 10% (v/v) fetal calf serum, 2 mMl-glutamine, 50 μg/ml streptomycin, and 50 IU/ml penicillin (Invitrogen, Breda, The Netherlands). Cells were maintained by serial passage.

For tumor inoculation, exponentially growing cells were harvested by trypsinization, washed twice in phosphate-buffered saline, and adjusted to a suspension containing 1.0 × 107 tumor cells/ml. Male WAG/Rij rats with a mean weight of 278 g (range 244–320 g) (Harlan/CPB, Zeist, The Netherlands), anesthetized using halothane, underwent laparotomy and tumor cells were inoculated at four sites by injecting 5 × 105 cells subcapsularly into the left and right main lobes and into the right accessory lobes of the liver. After inoculation in the liver the CC531 cells grew into solid tumors with a mean weight of 96 mg (range 55–220 mg) per tumor within 11 to 12 days.

Single-Pass Liver Perfusion.

The mean weight of the rats at the time of perfusion was 295 g (range 261–333 g). The animals were anesthetized by an intraperitoneal injection with a mixture of Hypnorm (0.315 mg/ml fentanyl citrate and 10 mg/ml fluanisone) (Janssen Pharmaceutics, Beerse, Belgium) and Dormicum (midazolam) (Roche Nederland B.V., Mijdrecht, The Netherlands) 11 to 12 days after tumor inoculation. A V-line abdominal incision was made. The gastroduodenal artery and the pyloric vein were tied off. The common hepatic artery was cannulated with polyethylene tubing-50 (∅ 0.61 mm). Perfusion of the liver was initiated upon cannulation of the portal vein with a 16-gauge double-needle cannula. The inferior caval vein above the kidneys was tied to ensure unidirectional flow, whereas the lower abdominal inferior caval vein close to the extremities was severed to allow immediate drainage. The diaphragm was then opened and a 16-gauge cannula was placed in the suprahepatic inferior caval vein through the right atrium to collect the outflow from the hepatic veins (Pang and Terrell, 1981). In orthograde single-pass perfusion the liver was perfused through the hepatic artery and portal vein using the caval vein for the outflow and in retrograde single-pass perfusion it was perfused through the hepatic artery and caval vein using the portal vein for the outflow. The liver was perfused in a once-through (single pass) system for 5, 10, 20, 30, or 40 min. Each group consisted of at least three rats.

The perfusion circuit consisted of a low-flow roller pump (Watson Marlow, de Jong, Rotterdam, The Netherlands), an infusion pump (perfusor; B. Braun, Melsungen, Germany), a collection reservoir/oxygenator (Bakkenes, Leiden University, The Netherlands), and a heat exchanger.

The perfusate, consisting of Gelofusine with 20% (v/v) outdated washed human erythrocytes (courtesy of the Bloodbank Leiden, Leiden, The Netherlands), was oxygenated (95% oxygen, 5% carbon dioxide) and kept at 37°C. The pH was adjusted to 7.4 with sodium hydrogen carbonate.

The liver was perfused from the portal vein (orthograde) or caval vein (retrograde) at a flow rate of 10 ml/min; the hepatic artery was perfused with perfusate at a flow rate of 1.0 ml/min to which melphalan was added by an infusion pump at a flow rate of 0.5 ml/min. Consequently, the melphalan concentration infused in the hepatic artery was 160 μM and 20.9 μM for the total perfusate. During the experiments bile flow remained constant.

Samples of the effluent of the caval vein or portal vein were taken, starting at the moment of infusion of melphalan. At the end of the perfusion a washout was performed with 30 ml of ice-cold saline during 3 min. After the liver was excised, the very solid tumors were excised and weighed. All samples were stored at −70°C until analysis.

High-Performance Liquid Chromatography (HPLC) Analysis.

The concentration of melphalan in the effluent samples as well as in tumor and liver tissue samples was measured using an HPLC assay. The HPLC apparatus consisted of a pump (P1000), an autosampler (AS300), a 100-μl injection loop, and a UV-detector (UV100) (all Spectra Series; Thermo Separation Products, Fremont, CA). Propylparaben was used as the internal standard. Methanol (HPLC-grade) was obtained from Biosolve (Valkenswaard, The Netherlands), perchloric acid (70% w/v) from Merck (Darmstadt, Germany), and acetic acid (100% v/v, extra pure) from Riedel de Haën (Seelze, Germany). Water was purified by reversed osmosis. The stock solution of melphalan was prepared in 2% (v/v) acetic acid in methanol, and the stock solution of propylparaben was prepared in demi-water.

Injections (25 μl) were made on a Novapak C18column (100 × 8 mm, dp = 4 μm; Waters, Milford, MA), protected by a Novapak C18 precolumn (10 × 8 mm,dp = 5 μm; Waters). The column was used at ambient temperature. The eluent comprised 46.5% (v/v) acetonitrile, 53.5% (v/v) water, and 0.03% (v/v) perchloric acid. The eluent flow rate was 2.0 ml/min and the UV detection wavelength was 262 nm. The dynamic range of detection of the HPLC assay was 0.16 to 81.19 μM. The interday coefficients of variation of the assay were 6 to 11% for the concentration range detected. Mean extraction efficiency was 95%.

Fifty microliters of perfusate, 25 mg of tumor tissue, or 50 mg of liver tissue was pipetted or weighed into a polypropylene microtube on ice. Next, 25 μl of the internal standard solution (2 μg/ml propylparaben in water) and 100 μl of absolute methanol (−80°C) were added. After vortex mixing all samples for 30 s, an ultrasonic treatment (liver, 10 min; tumor, 15 min) was performed at 0°C for only the tissue samples to extract all drug. After centrifuging at 11,000g for 5 min at 4°C the supernatant was transferred into an injection vial.

Statistical Analysis.

All data were analyzed with SPSS statistical software (version 9.0 for Windows; SPSS, Chicago, IL). Correlation coefficients were calculated using the paired Student'st test. For melphalan in serum and in perfusate we fitted a nonlinear mixed effects model, using the pharmacokinetic functionC · (1 − exp(−a ·t)) · (1 − exp(−b ·t)), with C as random effects for the rats (Lindstrom and Bates, 1990). The parameter C is the asymptote of the function, the ultimate value of melphalan in serum or perfusate. We tested for differences in C between the melphalan concentration of the outflow perfusate after orthograde and retrograde perfusion by also fitting separate values for Cfor each group and comparing the models with the likelihood ratio test. A p value <0.05 was considered statistically significant.

Results

We hypothesized that liver uptake of arterially infused melphalan will be reduced during single-pass retrograde IHP without affecting the tumor uptake compared with orthograde IHP. To test this, tumor-bearing rat livers were perfused in both perfusion modes for different periods of time. We used the same perfusion medium as during our clinical IHP program, Gelofusine, a modified gelatin plasma volume expander. At 10 μg/ml melphalan 29% was protein bound as determined by ultrafiltration. The melphalan concentration in the perfusate was based on the dose currently used in the clinical IHP (Vahrmeijer et al., 2000).

HPLC analysis revealed that tumor uptake of arterially infused melphalan was indeed unaffected by perfusion direction (Fig.2A): there was no difference in melphalan content of the tumor tissue at any time point. The tumor content seemed to increase roughly linearly for both perfusion directions: approximately 4.5 nmol/min/g tissue (Table1).

Figure 2
Figure 2

Tumor (A) and liver (B) concentration of melphalan in time during orthograde and retrograde liver perfusion with continuous melphalan infusion in the hepatic artery. ∗, statistical difference between orthograde and retrograde liver perfusion (p < 0.05). n = 3 for orthograde 5, 10, 20, and 40 min and for retrograde 10, 20, and 30 min;n = 4 for orthograde 30 min and for retrograde 5 and 40 min.

View this table:
Table 1

Rate of melphalan uptake in tumor and liver tissue for both perfusion directions

To the contrary, the melphalan uptake by liver tissue was strongly influenced by perfusion direction: the melphalan level after retrograde perfusion was much lower than after orthograde perfusion (Fig. 2B). The liver melphalan content seemed to increase linearly in the orthograde perfusion (0.8 nmol/min/g tissue) (Table 1). In the retrograde perfusion mode maximum melphalan content and steady state in the liver were already reached after 10 min (Fig. 2B).

The uptake by tumor tissue was much higher than by liver tissue in both perfusion directions (Fig. 3). The average tumor/liver uptake ratio from all separate time points was 6 for orthograde perfusion and 30 for retrograde perfusion.

Figure 3
Figure 3

Liver and tumor concentration of melphalan in time during orthograde (A) and retrograde (B) liver perfusion with continuous melphalan infusion in the hepatic artery. ∗, statistical difference between liver and tumor (p < 0.05). Forn values, see legend to Fig. 2.

The extraction of melphalan by the liver in both perfusion modes was determined by analyzing the melphalan concentration in the outflow perfusate (Fig. 4). A rapid extraction of melphalan occurred during the first 5 min, reaching steady state after 10 to 20 min for both perfusion directions. Apparently, the reduced melphalan uptake by the liver in the retrograde perfusion mode resulted in a significantly higher melphalan concentration in the outflowing perfusate than for the orthograde perfusion.

Figure 4
Figure 4

A, melphalan concentration in the outflowing perfusate of orthograde (■) and retrograde (▪) perfused livers. The difference between the two levels was calculated (see Materials and Methods) to be statistically significant (p < 0.05). For n values, see legend to Fig. 2. B, melphalan extraction by the liver. The difference between inflow concentration of melphalan (20.9 μM) and outflow concentration of orthograde (■) and retrograde (▪) perfused livers is calculated for each time point. The difference between the two levels was calculated to be statistically significant (p < 0.05). For n values, see legend to Fig. 2.

When melphalan tissue levels were converted to melphalan concentrations (assuming 1 g of tissue corresponds to 1 ml), the melphalan concentrations in tumor approached the melphalan inflow concentration (160 μM) in the hepatic artery after 40 min (Fig.5). The melphalan concentrations in the orthograde perfused liver also approached the inflow concentration in the liver sinusoid of 20.9 μM; the melphalan concentrations in retrograde perfused liver remained significantly lower.

Figure 5
Figure 5

Melphalan concentration during orthograde (A) and retrograde (B) perfusion in tumor tissue (●), liver tissue (○) and the outflow perfusate (▪) compared with the calculated inflow concentrations in the hepatic artery (——) and whole perfusate after mixing of the hepatic artery perfusate with the portal venous or caval venous perfusate (- - - -). For n values, see legend to Fig. 2.

Discussion

To maximize the effect of tumor treatment, melphalan exposure of the tumor should be as high as possible. However, at the same time toxicity to healthy cells increases with drug dose and therefore is dose-limiting. The concept of IHP is based on local administration of high drug doses to the liver that would be lethal if administered systemically but would not cause fatal hepatotoxicity in IHP. This study was performed to explore possibilities for further improvement of the current clinical IHP with melphalan (Vahrmeijer et al., 2000). The presented results clearly show that retrograde perfusion has a major advantage compared with orthograde perfusion, because retrograde perfusion markedly reduces the liver uptake of melphalan, and thus liver toxicity, without affecting the tumor uptake of melphalan.

Melphalan most likely exerts its cytotoxic effect, i.e., cell death, through the formation of interstrand and intrastrand DNA cross-links and DNA-protein cross-links by alkylation (Millar et al., 1986; Hansson et al., 1987). A linear correlation has been observed between the melphalan concentration and the level of DNA adducts: Tilby and colleagues showed this both in vitro as well as in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy (Tilby et al., 1993; Frank et al., 1996). Therefore, the cellular content of melphalan may be used as a biomarker for its cytotoxicity.

Our hypothesis that the melphalan uptake by the tumor would be unaffected by perfusion direction as long as the melphalan was infused in the hepatic artery is supported by our current results. We expected the uptake of melphalan by the liver, and thus most likely toxicity, to be less in retrograde single-pass perfusion, because it would probably only reach zone 1. The uptake in liver tissue was indeed strongly dependent on perfusion direction: the level after retrograde perfusion was only 20% that of normal perfusion direction, indicating that melphalan under retrograde flow conditions most likely reaches only the periportal hepatocytes of the liver sinusoids. Because these cells account for a maximum of one-third of the liver sinusoid (Watanabe et al., 1994) the tissue uptake ratio probably reflects the mass ratio of the tissue regions that are accessible for arterial input after orthograde or retrograde perfusion. The strongly reduced melphalan uptake in the retrograde perfused liver accounted for the higher melphalan concentration of the outflow perfusate in the retrograde perfusion: much less liver tissue was reached by the melphalan. Therefore, the distribution pattern of the hepatic artery in the liver, in contrast to liver tumors, is strongly affected by flow direction. Thus, our findings confirm that hepatic artery infusion of melphalan leads to a more selective tumor exposure (Chang et al., 1987; Kemeny et al., 1987; Hohn et al., 1989). The melphalan uptake in tumor tissue was much higher than in liver tissue for both perfusion directions.

Melphalan metabolism (conjugation and hydrolysis) was not assessed in this study. Our previous data on rat hepatic glutathione conjugation show that melphalan conjugates amounted to only 0.2 to 0.4% of the melphalan dose (Vahrmeijer et al., 1996). In bile and perfusate samples from patients treated by isolated hepatic perfusion with high-dose melphalan (200 mg) for liver metastases none of the melphalan conjugates were present at a detectable level in bile and perfusate samples (Vahrmeijer et al., 1996).

In addition to isolated hepatic perfusion, the cytostatic effects and the pharmacokinetics of melphalan have been assessed extensively in isolated limb perfusion studies. For example, Wu et al. (1997)developed a physiological pharmacokinetic model to describe the concentration-time profile of melphalan in perfusate and tissues in the isolated perfused rat hind limb during perfusion with melphalan.

In conclusion, retrograde IHP with continuous melphalan infusion in the hepatic artery provides a high tumor uptake of melphalan and probably reduced liver toxicity compared with orthograde perfusion. Because selective tumor exposure to melphalan is the sole objective of IHP, these findings justify the further exploration of retrograde liver perfusion. Preclinical studies involving retrograde IHP on pigs have already shown that retrograde IHP is technically feasible (van Ijken et al., 1998; Rothbarth et al., 2001). Therefore, a phase I clinical study will be started in our institute in the near future.

Acknowledgments

We thank Dr. K. S. Pang (Department of Pharmacology, University of Toronto, ON, Canada) for teaching the surgical techniques.

Footnotes

  • This study was supported by Grant 2000-2198 from the Dutch Cancer Society (to K.W.F.).

  • DOI: 10.1124/jpet.102.037895

  • Abbreviations:
    IHP
    isolated hepatic perfusion
    HPLC
    high-performance liquid chromatography
    dp
    particle density
    • Received April 23, 2002.
    • Accepted July 22, 2002.

References

  1. ↵
    1. Alexander HR, Jr,
    2. Bartlett DL,
    3. Libutti SK,
    4. Fraker DL,
    5. Moser T,
    6. Rosenberg SA
    (1998) Isolated hepatic perfusion with tumor necrosis factor and melphalan for unresectable cancers confined to the liver. J Clin Oncol 16:1479–1489.
    OpenUrlAbstract/FREE Full Text
  2. ↵
    1. Chang AE,
    2. Schneider PD,
    3. Sugarbaker PH,
    4. Simpson C,
    5. Culnane M,
    6. Steinberg SM
    (1987) A prospective randomized trial of regional versus systemic continuous 5-fluorodeoxyuridine chemotherapy in the treatment of colorectal liver metastases. Ann Surg 206:685–693.
    OpenUrlPubMed
  3. ↵
    1. Frank AJ,
    2. Proctor SJ,
    3. Tilby MJ
    (1996) Detection and quantification of melphalan-DNA adducts at the single cell level in hematopoietic tumor cells. Blood 88:977–984.
    OpenUrlAbstract/FREE Full Text
  4. ↵
    1. Hansson J,
    2. Lewensohn R,
    3. Ringborg U,
    4. Nilsson B
    (1987) Formation and removal of DNA cross-links induced by melphalan and nitrogen mustard in relation to drug-induced cytotoxicity in human melanoma cells. Cancer Res 47:2631–2637.
    OpenUrlAbstract/FREE Full Text
  5. ↵
    1. Hohn DC,
    2. Stagg RJ,
    3. Friedman MA,
    4. Hannigan JF, Jr,
    5. Rayner A,
    6. Ignoffo RJ,
    7. Acord P,
    8. Lewis BJ
    (1989) A randomized trial of continuous intravenous versus hepatic intraarterial floxuridine in patients with colorectal cancer metastatic to the liver: the Northern California Oncology Group trial. J Clin Oncol 7:1646–1654.
    OpenUrlAbstract
  6. ↵
    1. Kemeny N,
    2. Daly J,
    3. Reichman B,
    4. Geller N,
    5. Botet J,
    6. Oderman P
    (1987) Intrahepatic or systemic infusion of fluorodeoxyuridine in patients with liver metastases from colorectal carcinoma. A randomized trial. Ann Intern Med 107:459–465.
  7. ↵
    1. Lindstrom ML,
    2. Bates DM
    (1990) Nonlinear mixed effects models for repeated measures data. Biometrics 46:673–687.
    OpenUrlCrossRefPubMed
  8. ↵
    1. Marquet RL,
    2. Westbroek DL,
    3. Jeekel J
    (1984) Interferon treatment of a transplantable rat colon adenocarcinoma: importance of tumor site. Int J Cancer 33:689–692.
    OpenUrlPubMed
  9. ↵
    1. Millar BC,
    2. Tilby MJ,
    3. Ormerod MG,
    4. Payne AW,
    5. Jinks S,
    6. Loverock PS
    (1986) Comparative studies of total cross-linking, cell survival and cell cycle perturbations in Chinese hamster cells treated with alkylating agents in vitro. Biochem Pharmacol 35:1163–1169.
    OpenUrlCrossRefPubMed
  10. ↵
    1. Pang KS,
    2. Cherry WF,
    3. Accaputo J,
    4. Schwab AJ,
    5. Goresky CA
    (1988) Combined hepatic arterial-portal venous and hepatic arterial-hepatic venous perfusions to probe the abundance of drug metabolizing activities: perihepatic venous O-deethylation activity for phenacetin and periportal sulfation activity for acetaminophen in the once-through rat liver preparation. J Pharmacol Exp Ther 247:690–700.
    OpenUrlAbstract/FREE Full Text
  11. ↵
    1. Pang KS,
    2. Terrell JA
    (1981) Retrograde perfusion to probe the heterogeneous distribution of hepatic drug metabolizing enzymes in rats. J Pharmacol Exp Ther 216:339–346.
    OpenUrlAbstract/FREE Full Text
  12. ↵
    1. Rappaport AM
    (1980) Hepatic blood flow: morphologic aspects and physiologic regulation. Int Rev Physiol 21:1–63.
    OpenUrlPubMed
  13. ↵
    1. Rothbarth J,
    2. Tijl F,
    3. van Dierendonck JH,
    4. Pijl MEJ,
    5. Tollenaar RAEM,
    6. Kuppen PJK,
    7. van de Velde CJH,
    8. Schultze-Kool LJ
    (2001) Percutaneous isolated hepatic perfusion for treatment of liver metastases. Hepato-Pancreato-Biliary Association 3:115, , V31.5, Amsterdam, 30 May 2001..
  14. ↵
    1. Sigurdson ER,
    2. Ridge JA,
    3. Kemeny N,
    4. Daly JM
    (1987) Tumor and liver drug uptake following hepatic artery and portal vein infusion. J Clin Oncol 5:1836–1840.
    OpenUrlAbstract/FREE Full Text
  15. ↵
    1. Taylor I,
    2. Bennett R,
    3. Sherriff S
    (1978) The blood supply of colorectal liver metastases. Br J Cancer 38:749–756.
    OpenUrlPubMed
  16. ↵
    1. Tilby MJ,
    2. Newell DR,
    3. Viner C,
    4. Selby PJ,
    5. Dean CJ
    (1993) Application of a sensitive immunoassay to the study of DNA adducts formed in peripheral blood mononuclear cells of patients undergoing high-dose melphalan therapy. Eur J Cancer 29A:681–686.
  17. ↵
    1. Vahrmeijer AL,
    2. Snel CA,
    3. Steenvoorden DP,
    4. Beijnen JH,
    5. Pang KS,
    6. Schutrups J,
    7. Tirona R,
    8. Keizer HJ,
    9. van Dierendonck JH,
    10. van de Velde CJ,
    11. et al.
    (1996) Lack of glutathione conjugation of melphalan in the isolated in situ liver perfusion in humans. Cancer Res 56:4709–4714.
    OpenUrlAbstract/FREE Full Text
  18. ↵
    1. Vahrmeijer AL,
    2. van Dierendonck JH,
    3. Keizer HJ,
    4. Beijnen JH,
    5. Tollenaar RA,
    6. Pijl ME,
    7. Marinelli A,
    8. Kuppen PJ,
    9. van Bockel JH,
    10. Mulder GJ,
    11. et al.
    (2000) Increased local cytostatic drug exposure by isolated hepatic perfusion: a phase I clinical and pharmacologic evaluation of treatment with high dose melphalan in patients with colorectal cancer confined to the liver. Br J Cancer 82:1539–1546.
    OpenUrlCrossRefPubMed
  19. ↵
    1. van Ijken MG,
    2. de Bruijn EA,
    3. de Boeck G,
    4. ten Hagen TL,
    5. van der Sijp JR,
    6. Eggermont AM
    (1998) Isolated hypoxic hepatic perfusion with tumor necrosis factor-alpha, melphalan and mitomycin C using balloon catheter techniques: a pharmacokinetic study in pigs. Ann Surg 228:763–770.
    OpenUrlCrossRefPubMed
  20. ↵
    1. Wang LQ,
    2. Persson BG,
    3. Stenram U,
    4. Bengmark S
    (1994) Influence of portal branch ligation on the outcome of repeat dearterializations of an experimental liver tumor in the rat. J Surg Oncol 55:229–234.
    OpenUrlPubMed
  21. ↵
    1. Watanabe Y,
    2. Puschel GP,
    3. Gardemann A,
    4. Jungermann K
    (1994) Presinusoidal and proximal intrasinusoidal confluence of hepatic artery and portal vein in rat liver: functional evidence by orthograde and retrograde bivascular perfusion. Hepatology 19:1198–1207.
    OpenUrlCrossRefPubMed
  22. ↵
    1. Wu ZY,
    2. Smithers BM,
    3. Roberts MS
    (1997) Tissue and perfusate pharmacokinetics of melphalan in isolated perfused rat hindlimb. J Pharmacol Exp Ther 282:1131–1138.
    OpenUrlAbstract/FREE Full Text
View Abstract
Back to top

In this issue

Download PDF
Article Alerts
Email Article
Citation Tools

Research ArticleGASTROINTESTINAL, HEPATIC, PULMONARY, AND RENAL

Reduced Liver Uptake of Arterially Infused Melphalan during Retrograde Rat Liver Perfusion with Unaffected Liver Tumor Uptake

Joost Rothbarth, Rolf W. Sparidans, Jos H. Beijnen, Leo J. Schultze Kool, Hein Putter, Cornelis J. H. van de Velde and Gerard J. Mulder
Journal of Pharmacology and Experimental Therapeutics November 1, 2002, 303 (2) 736-740; DOI: https://doi.org/10.1124/jpet.102.037895
Permalink:
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section